Long-Term Follow-up of Fabry Disease Subjects Who Were Treated With ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy

To long-term follow-up of fabry disease subjects who were treated with ST-920, an AAV2/6 Human Alpha galactosidase a gene therapy

CT.gov Identifier
NCT05039866
EudraCT Identifier
N/A
CTIS:
2024-512700-18-00
Sponsor
Sangamo Therapeutics/TxCell
Collaborator
N/A
Study Contact Information
+1 510-970-6000
Recruiting
Contact Us

Study Details

Diseases
Fabry Disease
Study Drug
Isaralgagene civaparvovec
Genes
GLA
Study Dates
Aug 2021 - Mar 2029
Sex
Female & Male
Age
18+ years
Inclusion and Exclusion Criteria
Inclusion Criteria:
  • All subjects who have received ST-920 in separate parent trial and who have consented to participate in this Long Term Follow-up study.
  • Subjects who received ST-920 therapy in a separate parent trial
  • Subjects who have consented to participate in this LTFU study.
Exclusion Criteria:
  • This study has no exclusion criteria

Protocol Summary

To long-term follow-up of fabry disease subjects who were treated with ST-920, an AAV2/6 Human Alpha galactosidase a gene therapy

Study Locations

To view all trial locations, click here

Contact Us About More Information for the Clinical Trial Concierge Service

Natera’s Clinical Trial Concierge Program is comprised of a dedicated team that helps connect providers and patients with appropriate clinical trials. To learn more about a trial offered through this service, please complete the form below.  

Fields marked with asterisk (*) are mandatory.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.